The clinical development of inhibitors of poly(ADP-ribose) polymerase.
about
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitroBreast cancer chemoprevention: old and new approachesPARP expression in germ cell tumoursDiscordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.Complexes of mismatched and complementary DNA with minor groove binders. Structures at nucleotide resolution via an improved hydroxyl radical cleavage methodology.Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury.The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.Inverse susceptibility to oxidative death of lymphocytes obtained from Alzheimer's patients and skin cancer survivors: increased apoptosis in Alzheimer's and reduced necrosis in cancer.'BRCAness' and its implications for platinum action in gynecologic cancer.Loss of BRCA1 expression leads to worse survival in patients with gastric carcinomaBest practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.The diverse and complex roles of NF-κB subunits in cancer.The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunityAntidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models.The development of PARP as a successful target for cancer therapy.PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.Novel approaches to treatment of leiomyosarcomas.
P2860
Q24615499-9696BAFF-358E-4F36-A71A-CE3C7E366D0CQ27693259-FACA694E-E01C-44F3-BDDA-046438CC1DE2Q28287131-00B11951-86DF-491A-B9A3-CE131043F096Q33953822-F0F286D3-D233-41D2-9B49-9D9E3F5825E7Q35300516-8D3A4BF3-9CC2-4DD9-90B9-0AA68521EF16Q35514172-02F563E5-AD25-41EE-943B-F454140B119CQ35622211-A20F557A-3817-488C-A1FC-DB1687686170Q36222245-6420371F-AC4A-4F12-ADC1-5B7914B0476AQ36380704-3FAB68AA-3110-4C9F-8DE2-8733308369F0Q36731204-676DF8BC-A06A-49CA-9A9C-374BC0C8093BQ37561973-C14F694A-571E-4DA5-B3C5-0E3BDDAE7218Q37976939-3D9109B7-0210-4975-8024-5BF3E5D0927AQ38142158-D552E095-4CD4-4381-8E1C-9A930C7666CCQ38631373-8B2613FC-CBB6-4552-BA19-B3DD30CAEED8Q39245474-0AD930D6-1A1A-4FDB-8369-ABC3C1A22780Q47148667-DDA1A591-D005-4D87-8D75-CFCC606EA66EQ47278103-C6FBE493-87B4-41E2-8C1B-276058E5987AQ50980480-E59E7E91-8A1D-4F4E-99A8-A174E0A5F412Q54595774-06103D2E-E93D-4790-8D00-7EE39AD74DFF
P2860
The clinical development of inhibitors of poly(ADP-ribose) polymerase.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The clinical development of inhibitors of poly
@nl
The clinical development of inhibitors of poly(ADP-ribose) polymerase.
@en
type
label
The clinical development of inhibitors of poly
@nl
The clinical development of inhibitors of poly(ADP-ribose) polymerase.
@en
prefLabel
The clinical development of inhibitors of poly
@nl
The clinical development of inhibitors of poly(ADP-ribose) polymerase.
@en
P2860
P356
P1433
P1476
The clinical development of inhibitors of poly(ADP-ribose) polymerase
@en
P2093
P2860
P356
10.1093/ANNONC/MDQ667
P478
22 Suppl 1
P577
2011-01-01T00:00:00Z